[1] Schlumberger MJ, Torlantano M. Papillary and follicular thyroid carcinoma[J]. Best Pract Res Clin Endocrinol Metab, 2000, 14(4):601-613.  doi: 10.1053/beem.2000.0105
[2] Makeieff M, Burcia V, Raingeard I, et al. Positron emission tomography-computed tomography evaluation for recurrent differentiated thyroid carcinoma[J]. Eur Ann Otorhinolaryngol Head Neck Dis, 2012, 129(5):251-256.  doi: 10.1016/j.anorl.2012.01.003
[3] Sherman SI. Thyroid carcinoma[J]. Lancet, 2003, 361(9356):501-511.  doi: 10.1016/S0140-6736(03)12488-9
[4] Stokkel MP, Duchateau CS, Dragoiescu C. The value of FDG-PET in the follow-up of differentiated thyroid cancer:a review of the literature[J]. Q J Nucl Med Mol Imaging, 2006, 50(1):78-87.
[5] Lee JW, Lee SM, Lee DH, et al. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer:dual-center experience with 286 patients[J]. J Nucl Med, 2013, 54(8):1230-1236.  doi: 10.2967/jnumed.112.117119
[6] Shammas A, Degirmenci B, Mountz JM, et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer[J]. J Nucl Med, 2007, 48(2):221-226.
[7] Von Schulthess GK, Hany TF. Imaging and PET-PET/CT imaging[J]. J Radiol, 2008, 89(3 Pt 2):438-448.
[8] Townsend DW. Dual-modality imaging:combining anatomy and function[J]. J Nucl Med, 2008, 49(6):938-955.  doi: 10.2967/jnumed.108.051276
[9] Bannas P, Derlin T, Groth M, et al. Can 18F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative 131I whole body scan?[J]. Ann Nucl Med, 2012, 26(1):77-85.
[10] Bertagna F, Bosio G, Biasiotto G, et al. 18F FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative 131I total body scan and high thyroglobulin level[J]. Clin Nucl Med, 2009, 34(11):756-761.  doi: 10.1097/RLU.0b013e3181b7d95c
[11] Ko MS, Lee JH, Shong YK, et al. Normal and abnormal sonographic findings at the thyroidectomy sites in postoperative patients with thyroid malignancy[J]. AJR Am J Roentgenol, 2010, 194(6):1596-1609.  doi: 10.2214/AJR.09.2513
[12] Vural GU, Akkas BE, Ercakmak N, et al. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels:correlation with clinical and histopathologic characteristics and long-term follow-up data[J]. Clin Nucl Med, 2012, 37(10):953-959.  doi: 10.1097/RLU.0b013e31825b2057
[13] Torlontano M, Attard M, Crocetti U, et al. Follow-up of low risk patients with papillary thyroid cancer:role of neck ultrasonography in detecting lymph node metastases[J]. J Clin Endocrinol Metab, 2004, 89(7):3402-3407.  doi: 10.1210/jc.2003-031521
[14] Rosário PW, De Faria S, Bicalho L, et al. Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma[J]. J Ultrasound Med, 2005, 24(10):1385-1389.  doi: 10.7863/jum.2005.24.10.1385
[15] 滕卫平, 刘永峰, 高明, 等.甲状腺结节和分化型甲状腺癌诊治指南[J].中国肿瘤临床, 2012, 33(17):1249-1272.
[16] David A, Blotta A, Rossi R, et al. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma[J]. Thyroid, 2005, 15(2):158-164.  doi: 10.1089/thy.2005.15.158
[17] Ozkan E, Aras G, Kucuk NO. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results[J]. Clin Nucl Med, 2013, 38(5):326-331.  doi: 10.1097/RLU.0b013e318286827b
[18] Ozkan E, Soydal C, Araz M, et al. The additive clinical value of 18F-FDG PET/CT in defining the recurrence of disease in patients with differentiated thyroid cancer who have isolated increased antithyroglobulin antibody levels[J]. Clin Nucl Med, 2012, 37(8):755-758.  doi: 10.1097/RLU.0b013e31825ae77b